Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

Fig. 4

Estimated overall survival curve, by tumor subtype for study population (N = 20,033)

OS, overall survival; HR + , presence of hormone receptor; HR − , absence of hormone receptor; HER2 + , human epidermal growth factor receptor 2 (HER2) protein overexpression; HER2 − , no HER2 protein overexpression; TN, triple negative

Back to article page